Related references
Note: Only part of the references are listed.Severe hypoglycemia associated with use of trimethoprim/sulfamethoxazole in a patient with chronic renal insufficiency
Jamie M. Rosini et al.
ANNALS OF PHARMACOTHERAPY (2008)
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: Evidence for mechanism-based inhibition of CYP2C8 in vivo
A. Tornio et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide
Annikka Kalliokoski et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Severe hypoglycemia from clarithromycin-repaglinide drug interaction
Mogher Khamaisi et al.
PHARMACOTHERAPY (2008)
Proposal for a new tool to evaluate drug interaction cases
John R. Horn et al.
ANNALS OF PHARMACOTHERAPY (2007)
Severe and protracted hypoglycaemia associated with co-trimoxazole use
EL Strevel et al.
LANCET INFECTIOUS DISEASES (2006)
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics
M Niemi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs - Clinical relevance
J Kirchheiner et al.
CLINICAL PHARMACOKINETICS (2005)
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects
M Niemi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide
TB Bidstrup et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively
X Wen et al.
DRUG METABOLISM AND DISPOSITION (2002)
Clinical pharmacokinetics and pharmacodynamics of repaglinide
V Hatorp
CLINICAL PHARMACOKINETICS (2002)
Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment
S Schumacher et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Pharmacokinetics of repaglinide in subjects with renal impairment
TC Marbury et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
